Login to Your Account



Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece

By Cormac Sheridan


Wednesday, July 16, 2008
Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) in up-front, development and sales-related milestones. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription